Intellia Therapeutics (NTLA) Form 3 Intellia Therapeutics / Birgit C Schultes ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Schultes Birgit C

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET, SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/13/2025

3. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
EVP, Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	67,615(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	10/01/2027	Common Stock	40,000	27.33	D
Stock Option (right to buy)	(3)	12/11/2027	Common Stock	20,000	18.3	D
Stock Option (right to buy)	(4)	12/17/2028	Common Stock	10,625	14.58	D
Stock Option (right to buy)	(5)	03/01/2030	Common Stock	30,000	13.4	D
Stock Option (right to buy)	(6)	03/02/2031	Common Stock	20,600	57.71	D
Stock Option (right to buy)	(7)	09/30/2031	Common Stock	3,500	134.06	D
Stock Option (right to buy)	(8)	02/28/2033	Common Stock	24,965	40.75	D
Stock Option (right to buy)	(9)	02/28/2034	Common Stock	31,816	32.66	D

Explanation of Responses:

1. Includes (i) a grant of 16,080 restricted stock units, (ii) a grant of 7,500 restricted stock units, (iii) a grant of 3,440 restricted stock units, (iiii) a grant of 400 restricted stock units, (v) a grant of 20,839 restricted stock units, (vi) a grant of 17,668 restricted stock units, and (vii) a grant of 22,045 restricted stock units, each representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on October 2, 2017 with respect to 40,000 shares of Common Stock, with 25% vesting on September 18, 2018 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.

3. This option was granted on December 12, 2017 with respect to 20,000 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.

4. This option was granted on December 18, 2018 with respect to 30,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.

5. This option was granted on March 2, 2020 with respect to 30,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.

6. This option was granted on March 3, 2021 with respect to 20,600 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.

7. This option was granted on October 1, 2021 with respect to 3,500 shares of Common Stock, with 25% vesting on October 1, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter.

8. This option was granted on March 1, 2023 with respect to 24,965 shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in twenty-four (24) substantially equal monthly installments thereafter.

9. This option was granted on March 1, 2024 with respect to 31,816 shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in twenty-four (24) substantially equal monthly installments thereafter.

Remarks:

Exhibit 24.1 - Power of Attorney.

	James Basta, attorney-in-fact	01/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.